There are few things more important than health, but a recent report suggests that the public has declining trust in traditional healthcare institutions to protect theirs.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh